By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Jazz Pharmaceuticals 

Corporate Headquarters
Fourth Floor, Connaught House

One Burlington Road
Dublin    4  Ireland
Phone: 353-1-634-7800 Fax: 353-1-634-7850


Jazz Pharmaceuticals plc is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs. We have a diverse portfolio of products and product candidates, with a focus in the areas of sleep and hematology/oncology. We also support commercial products in therapeutic areas where we can meaningfully address serious medical needs.

As part of our unwavering commitment to improve patients’ lives, we continue to expand our commercial product portfolio and our research and development pipeline in therapeutic areas that can leverage our unique expertise. We do this through a growth strategy of growing sales of the existing products in our portfolio; acquiring additional differentiated products that are on the market or product candidates that are in late-stage development; and pursuing focused development of a pipeline of post-discovery differentiated product candidates.

Our Culture

We have a strong patient-focused culture at Jazz Pharmaceuticals that our employees believe in and pursue every day. It is clearly identified through our mission, vision and core values. Each member of our team makes integral contributions and is working toward a common goal to improve patients' lives. Everything we do at Jazz Pharmaceuticals is focused on three things:
• Putting patients first
• Being a great place to work
• Living our core values — integrity, collaboration, passion, pursuit of excellence and innovation

Key Statistics

Ownership: Public

Web Site: Jazz Pharma
Symbol: JAZZ


Company News
Jazz Pharma (JAZZ) Initiates Rolling NDA Submission For Vyxeos (CPX-351) Expects To Complete NDA Submission By Early 2017 10/3/2016 6:42:11 AM
Jazz Pharma (JAZZ) Announces That Patient Enrollment Is Complete For The Phase 3 Studies Of JZP-110 Evaluating Excessive Sleepiness In Obstructive Sleep Apnea 9/27/2016 6:58:25 AM
Good or Bad? Pharma Bro Thinks Jazz Pharma (JAZZ) Could be Worth $20 Billion, Calls Mast Therapeutics (MSTX) 'Worthless' 9/13/2016 6:03:55 AM
Jazz Pharma (JAZZ) To Present At The Morgan Stanley (MST) Global Healthcare Conference 9/8/2016 10:03:23 AM
4 Cheap Biotech Stocks Ready to Fly 8/16/2016 8:40:56 AM
Jazz Pharma (JAZZ) Announces Second Quarter 2016 Financial Results 8/10/2016 10:02:51 AM
Jazz Pharma (JAZZ) Release: CMS Grants New Technology Add-On Payment To Defitelio For The Treatment Of Hepatic Veno-Occlusive Disease With Renal Or Pulmonary Dysfunction Following Hematopoietic Stem-Cell Transplantation 8/3/2016 9:36:56 AM
San Diego's Pfenex (PFNX) Snags a $181 Million+ Hematological Malignancies Deal With Jazz Pharma (JAZZ) 7/29/2016 6:03:15 AM
Jazz Pharma (JAZZ) To Report 2016 Second Quarter Financial Results On August 9, 2016 7/26/2016 6:32:17 AM
Jazz Pharma (JAZZ) Announces Results Of Tender Offer To Purchase All Of The Outstanding Shares Of Common Stock Of Celator Pharma (CPXX) 7/12/2016 6:07:36 AM